{"altmetric_id":3308836,"counts":{"readers":{"mendeley":39,"citeulike":1,"connotea":0},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":3},"total":{"posts_count":3}},"citation":{"abstract":"This long-term study was designed to further characterise the retinal safety profile of insulin glargine and human neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes mellitus.","abstract_source":"pubmed","altmetric_jid":"4f6fa6143cf058f610007106","authors":["J Rosenstock","V Fonseca","J B McGill","M Riddle","J-P Hall\u00e9","I Hramiak","P Johnston","M Davis","J. Rosenstock","V. Fonseca","J. B. McGill","M. Riddle","J.-P. Hall\u00e9","I. Hramiak","P. Johnston","M. Davis"],"doi":"10.1007\/s00125-009-1415-7","endpage":"1788","first_seen_on":"2015-02-04T10:03:25+00:00","handles":[],"isbns":[],"issns":["1432-0428","0012-186X"],"issue":"9","journal":"Diabetologia","last_mentioned_on":1448928000,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19526210?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum","http:\/\/dx.doi.org\/10.1007\/s00125-009-1415-7","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19526210","http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2723680","http:\/\/rd.springer.com\/article\/10.1007\/s00125-009-1415-7"],"pdf_url":"http:\/\/link.springer.com\/content\/pdf\/10.1007%2Fs00125-009-1415-7.pdf","pmcid":"PMC2723680","pmid":"19526210","pubdate":"2009-09-01T00:00:00+00:00","publisher":"Springer-Verlag","publisher_subjects":[{"name":"Human Physiology","scheme":"springer"},{"name":"Internal Medicine","scheme":"springer"},{"name":"Medicine & Public Health","scheme":"springer"},{"name":"Metabolic Diseases","scheme":"springer"},{"name":"Clinical Sciences","scheme":"era"},{"name":"Paediatrics And Reproductive Medicine","scheme":"era"},{"name":"Public Health And Health Services","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"1778","subjects":["endocrinology"],"title":"Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study","type":"article","uri":"http:\/\/link.springer.com\/10.1007\/s00125-009-1415-7","volume":"52","mendeley_url":"http:\/\/www.mendeley.com\/research\/similar-progression-diabetic-retinopathy-insulin-glargine-neutral-protamine-hagedorn-nph-insulin-pat-3"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7027828,"mean":6.2647750304584,"rank":1648831,"this_scored_higher_than_pct":64,"this_scored_higher_than":4555580,"rank_type":"exact","sample_size":7027828,"percentile":64},"similar_age_3m":{"total_number_of_other_articles":231370,"mean":7.9599484632774,"rank":64175,"this_scored_higher_than_pct":70,"this_scored_higher_than":163627,"rank_type":"exact","sample_size":231370,"percentile":70},"this_journal":{"total_number_of_other_articles":1884,"mean":14.749161975571,"rank":672,"this_scored_higher_than_pct":50,"this_scored_higher_than":942,"rank_type":"exact","sample_size":1884,"percentile":50},"similar_age_this_journal_3m":{"total_number_of_other_articles":53,"mean":26.348653846154,"rank":29,"this_scored_higher_than_pct":45,"this_scored_higher_than":24,"rank_type":"exact","sample_size":53,"percentile":45}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":4,"Librarian":2,"Researcher":8,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":5,"Student  > Postgraduate":2,"Student  > Master":5,"Other":4,"Student  > Bachelor":1,"Lecturer":3,"Lecturer > Senior Lecturer":1,"Professor":2},"by_discipline":{"Engineering":1,"Medicine and Dentistry":26,"Neuroscience":2,"Agricultural and Biological Sciences":6,"Computer Science":2,"Nursing and Health Professions":2}}},"geo":{"mendeley":{"CA":1,"NL":1,"HK":1,"US":1,"JP":1,"PT":1,"DE":2}}},"posts":{"policy":[{"title":"Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units\/ml (Toujeo)","url":"https:\/\/www.nice.org.uk\/guidance\/esnm62\/resources\/type-1-diabetes-mellitus-in-adults-highstrength-insulin-glargine-300-unitsml-toujeo-pdf-1502681101863109","license":"public","citation_ids":[4228329,15771736,3308836,786738,4228329,15771736,3308836,786738],"posted_on":"2015-10-01T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/advice\/esnm62\/chapter\/Key-points-from-the-evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-3f9ce2520181aac4190dbdf9cd850074643fad1a2bbb7796a23f5ab6943d47c6.jpg"}},{"title":"Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units\/ml (Toujeo)","url":"https:\/\/www.nice.org.uk\/guidance\/esnm65\/resources\/type-2-diabetes-mellitus-in-adults-highstrength-insulin-glargine-300-unitsml-toujeo-pdf-1502681106901957","license":"public","citation_ids":[15771736,3308836,786738,2562337,2665728,3064763,4228329,4166928,4228329,15771736,3863259,4505961,3308836,786738],"posted_on":"2015-12-01T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/advice\/esnm65\/chapter\/Key-points-from-the-evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-cf0ad56b2e1ef1555f5bec5044944404a10ea30db564a5d909d53fad4eeaf483.jpg"}},{"title":"Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar)","url":"https:\/\/www.nice.org.uk\/guidance\/esnm64\/resources\/diabetes-mellitus-type-1-and-type-2-insulin-glargine-biosimilar-abasaglar-pdf-1502681105222341","license":"public","citation_ids":[3308836,786738,3995281,3956362,3308836,786738],"posted_on":"2015-12-01T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/advice\/esnm64\/chapter\/Key-points-from-the-evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-37ddc7dd0195119d4f4b560f60d51b93c4037a898c341c77adefc3189c8481f8.jpg"}}]}}